Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) EBT (2022 - 2025)

Historic EBT for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Q3 2025 value amounting to -$30.0 million.

  • Phathom Pharmaceuticals' EBT rose 6498.03% to -$30.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$274.4 million, marking a year-over-year increase of 1914.08%. This contributed to the annual value of -$334.3 million for FY2024, which is 6599.37% down from last year.
  • Per Phathom Pharmaceuticals' latest filing, its EBT stood at -$30.0 million for Q3 2025, which was up 6498.03% from -$75.7 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year EBT high stood at -$30.0 million for Q3 2025, and its period low was -$94.3 million during Q1 2025.
  • For the 4-year period, Phathom Pharmaceuticals' EBT averaged around -$62.2 million, with its median value being -$55.0 million (2022).
  • In the last 5 years, Phathom Pharmaceuticals' EBT tumbled by 12319.86% in 2024 and then skyrocketed by 6498.03% in 2025.
  • Quarter analysis of 4 years shows Phathom Pharmaceuticals' EBT stood at -$55.0 million in 2022, then plummeted by 44.76% to -$79.6 million in 2023, then rose by 6.36% to -$74.5 million in 2024, then skyrocketed by 59.78% to -$30.0 million in 2025.
  • Its EBT stands at -$30.0 million for Q3 2025, versus -$75.7 million for Q2 2025 and -$94.3 million for Q1 2025.